Pfizer Inc.
Pfizer at a decision point: is the multi-decade correction over, or does the patent cliff force one last low?
Published Oct 23, 2026 · Updated Oct 23, 2026 · by EllTec Analysis · ~35 min read · How to read this analysis →
Disclosure: the EllTec Analysis Tracking Portfolio currently holds no position in PFE. (as of Oct 30, 2026)
For information and education only. Not investment advice. See the full disclaimer for details.
Some sections of this analysis are Premium-only.
EllTec Analysis Score
−6Fairly valued
Scale −100 to +100 · 0 = fairly valued
Sector comparison
0Fairly valued
Health Care · 199 reference companies
higher than 47 % of them
Global comparison
−15Slightly overvalued
1984 leading companies worldwide
Rank 19 of 34 stocks covered by EllTec Analysis
▸ Details: pillars and key figures
The five pillars
Average rank of the pillar's figures, 0 to 100: 50 is the middle of the comparison group, higher is better (for valuation: cheaper).
Valuation
Sector 60 · Global 47
Profitability & quality
Sector 58 · Global 62
Growth (past and expected)
Sector 6 · Global 9
Financial stability
Sector 28 · Global 28
Capital allocation & earnings quality
Sector 88 · Global 85
P/E ratio (trailing)(lower is better)
PFE39.5x
Sector median35.6x
Global median22.8x
Forward P/E(lower is better)
PFE10.9x
Sector median20.8x
Global median16.6x
EV/EBITDA(lower is better)
PFE8.8x
Sector median17.5x
Global median12.7x
EV/Sales(lower is better)
PFE3.5x
Sector median4.8x
Global median3.1x
Free cash flow yield
PFE6.4 %
Sector median3.6 %
Global median4.4 %
Return on invested capital (ROIC)
PFE13.5 %
Sector median11.8 %
Global median10.7 %
Operating margin
PFE29.6 %
Sector median18.2 %
Global median16.6 %
Expected revenue growth p.a. (3 years)
PFE-4.2 %
Sector median8.3 %
Global median6.7 %
Expected EPS growth p.a. (3 years)
PFE-8.5 %
Sector median12.3 %
Global median12.3 %
Revenue growth p.a. (last 3 years)
PFE-14.8 %
Sector median9.1 %
Global median5.4 %
EPS growth p.a. (last 3 years)
PFE-37.1 %
Sector median8.4 %
Global median6.1 %
PEG ratio (P/E ÷ EPS growth)(lower is better)
PFEearnings falling
Sector median2.0x
Global median1.6x
Debt/EBITDA(lower is better)
PFE2.4x
Sector median2.1x
Global median2.2x
Piotroski F-Score (0–9)
PFE7
Sector median6
Global median6
Shareholder yield (dividends + buybacks)
PFE5.4 %
Sector median1.4 %
Global median2.6 %
25 of 25 figures available. Figures as of October 23, 2026, EllTec Analysis Score published October 27, 2026. Recalculated every weekend.
Basis: reported company figures and analyst consensus estimates (via stockanalysis.com), calculated by EllTec Analysis. The EllTec Analysis Score is a quantitative assessment, not investment advice, and does not replace the analysis below.
EllTec Analysis Fear & Greed Index
Region: USA · Oct 30, 2026
48
Neutral
1 week: +3 · 1 month: −7 · 1 year: ±0
🔒 EllTec Analysis Risk/Reward Score
One number from 0 to 100 that combines the price targets, the probability of the scenarios, the entry zone, the risk assessment, the macro backdrop and the fundamentals of this analysis. Available to subscribers.
From €24.17 per month
Unlock now →Macro backdrop
Region: USA
+27
Tailwind for the market
Interactive chartPfizer Inc.PFE
Switch the time frame (minutes to months), zoom, scroll and draw your own lines.
The chart is provided by TradingView. Loading it transfers data such as your IP address to TradingView. Your choice is remembered in this browser. Privacy policy
More analyses in Stocks
All Stocks analyses →
Volkswagen AG
Wave II in its final zone: the preferred share trades within the 0.618 to 0.786 retracement and on its strongest volume support of two decades.
Alibaba Group
The Floor Is In
FMC Corporation
A four-year decline for an agricultural science company
New analyses by email
EllTec Analysis Updates: a short email whenever a new analysis is published or a scenario changes. Free, unsubscribe any time.
Newsletter →